+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Solid Tumor Drug"

Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020 - Product Thumbnail Image

Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 39 Pages
  • Global
From
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020 - Product Thumbnail Image

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform - Pipeline Review, H1 2020

  • Drug Pipelines
  • January 2020
  • 112 Pages
  • Global
From
Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019 - Product Thumbnail Image

Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019

  • Drug Pipelines
  • August 2019
  • 100 Pages
  • Global
From
Solid Tumor Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Solid Tumor Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • November 2023
  • 120 Pages
  • Global
From
Solid Tumor Therapeutics Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Solid Tumor Therapeutics Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application

  • Report
  • August 2021
  • 109 Pages
  • Global
From
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 81 Pages
  • Global
From
TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021 - Product Thumbnail Image

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drugs in Development, 2021 - Product Thumbnail Image

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2019

  • Drug Pipelines
  • April 2019
  • 85 Pages
  • Global
From
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019 - Product Thumbnail Image

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019

  • Drug Pipelines
  • March 2019
  • 97 Pages
  • Global
From
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018 - Product Thumbnail Image

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018

  • Drug Pipelines
  • August 2018
  • 74 Pages
  • Global
From
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H1 2018 - Product Thumbnail Image

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H1 2018

  • Drug Pipelines
  • June 2018
  • 53 Pages
  • Global
From
Loading Indicator

The Solid Tumor Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Solid Tumor Drugs are used to treat solid tumors, which are tumors that form a mass of abnormal cells. These drugs are used to reduce the size of the tumor, slow its growth, and reduce the spread of cancer cells. Solid Tumor Drugs can be administered orally, intravenously, or through injections. They can also be used in combination with other treatments such as radiation and chemotherapy. The Solid Tumor Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. Other companies in the market include AstraZeneca, Eli Lilly, Amgen, and Johnson & Johnson. Show Less Read more